Kenvue (KVUE) Q1 2026 earnings review
Margins Surge While Deal Looms, But Volumes Tell a Cautious Story
Kenvue's Q1 results are overshadowed by the pending Kimberly-Clark acquisition, but the standalone numbers reveal a bifurcated business. While reported revenue grew 4.5%, this was heavily flattered by a 3.8% FX tailwind; organic volume actually declined 0.3%. The real achievement was profitability. Adjusted Operating Margin reversed its recent sluggishness, accelerating to 24.0% and driving a 33% surge in Adjusted EPS to $0.32. Skin Health finally reversed its persistent declines, but Self Care suddenly stumbled due to a weak flu season. With forward guidance suspended ahead of the H2 2026 merger close, the operational turnaround is taking a back seat to deal execution.
🐂 Bull Case
Adjusted operating margin expanded an impressive 420 basis points YoY to 24.0%, driven by 'Our Vue Forward' supply chain optimization and reduced SG&A expenses. Cost controls are accelerating earnings growth far beyond revenue.
After a grueling 2025, Skin Health & Beauty reversed its negative trajectory, posting 5.0% organic growth on the back of a strong 4.2% volume recovery, validating recent brand investments.
🐻 Bear Case
The traditionally defensive Self Care segment saw organic sales reverse to a 2.3% decline, severely impacted by a 3.9% drop in volume. Weak cold and flu seasons exposed the segment's vulnerability to macro/environmental shifts.
The reported 4.5% net sales growth is deceptive. Stripping out a massive 3.8% FX benefit, organic growth was only 0.7%, and total volume actually contracted 0.3%. Growth is entirely reliant on pricing and currency.
⚖️ Verdict: ⚪
Neutral. The massive margin improvement is commendable, but the lack of organic volume growth and the frozen guidance due to the pending Kimberly-Clark acquisition effectively anchors the stock to the deal price, limiting standalone catalysts.
Key Themes
Skin Health & Beauty Reversal
The most positive fundamental shift in the quarter was Skin Health & Beauty. The segment reversed from a 4.8% organic sales decline in 25Q1 to a robust 5.0% organic growth rate in 26Q1. Crucially, this was accelerating on a volume basis (+4.2%). Management cited strong brand activations and product pipeline strength, specifically naming the entry of Neutrogena Sun into EMEA and the launch of OGX Pro Growth in North America/EMEA.
Aggressive Margin Expansion Accelerating
Profitability is accelerating significantly. Adjusted gross margin expanded 80 bps YoY to 60.8%, fully absorbing inflation, tariffs, and lower volume leverage. Even more impressive, Adjusted Operating Margin expanded 420 bps to 24.0%. The 'Our Vue Forward' cost optimization program is delivering tangible results, specifically lowering SG&A expenses and improving media ROI.
Targeted eCommerce Accelerating Distribution
Management explicitly cited targeted actions in the eCommerce channel as a key driver for both the Skin Health & Beauty recovery and the Essential Health (Baby Care) expansion in North America. By shifting focus to digital distribution, the company is successfully augmenting traditional retail channels.
Self Care Volume Decelerating Rapidly
Previously the backbone of Kenvue's stability, Self Care reversed into negative territory. Organic sales fell 2.3%, dragged down by a sharp 3.9% volume contraction. Management blamed weak cold and flu seasons across major markets. While Zyrtec gained share via a new PGA TOUR sponsorship, the broader segment is lagging the company average.
Macro FX Tailwinds Masking Volume Weakness
Management touted 'encouraging' net sales growth of 4.5%. However, this narrative contradicts the underlying data: 3.8% of this growth was a pure foreign currency benefit. Overall organic volume actually declined 0.3%. The company is relying almost entirely on price realization and macro FX shifts to generate top-line expansion, a trend that is not sustainably stable.
Heavy Restructuring Costs Despite Looming Merger
Despite the Kimberly-Clark acquisition closing in H2 2026, Kenvue's Board approved a new '2026 Restructuring Initiative' in February aimed at transforming the supply chain and operating model. This carries $250 million in pre-tax charges for FY26 ($71M already realized in Q1). Pushing a massive standalone restructuring right before integration execution adds significant organizational complexity.
Other KPIs
Stable. The segment delivered 1.5% organic growth, nicely balanced by 1.4% volume growth and 0.1% price/mix. Growth was supported by the global restage of Listerine and new 'On-The-Go' product formats, offsetting declines in Women's Health.
Accelerating significantly from $200 million in 25Q1. Driven entirely by the $152M YoY increase in net income and a disciplined $100M reduction in capital expenditures. Total cash remains stable at $1.1 billion.
Guidance
Reversing narrative. Due to the pending acquisition by Kimberly-Clark, which passed the Hart-Scott-Rodino waiting period in February and is slated to close in H2 2026, Kenvue has entirely withdrawn all forward-looking financial guidance and canceled its earnings conference call.
Key Questions
Restructuring vs. Integration
Given the pending Kimberly-Clark transaction expected in H2 2026, why initiate a new $250M '2026 Restructuring Initiative' now? How much of this cost is standalone optimization versus pre-merger integration prep?
Self Care Underlying Health
Self Care volume declined 3.9% due to weak cold/flu seasons. If we normalize for the macro weather/illness effect, what was the underlying volume growth or market share capture in the core OTC portfolio?
Pricing Power Fatigue
Total organic volume was down 0.3%, but price/mix was up 1.0%. Are you seeing any pushback or elasticities from retailers/consumers on pricing, particularly in regions where FX isn't providing a translation benefit?